The coronary heart disease diagnostic imaging market was valued at an estimated USD 5.84 billion in 2025, is projected to reach USD 6.16 billion in 2026, and is forecast to expand to USD 10.65 billion by 2036 at a CAGR of 5.6%. Demand is being reshaped by first-line CCTA adoption, wider use of PET and perfusion MRI in complex cases, and more selective use of invasive angiography with pressure and intravascular imaging support.
| Parameter | Details |
|---|---|
| Market value (2026) | USD 6.16 billion |
| Forecast value (2036) | USD 10.65 billion |
| CAGR (2026 to 2036) | 5.6% |
| Estimated market value (2025) | USD 5.84 billion |
| Incremental opportunity | USD 4.49 billion |
| Leading modality | Coronary computed tomography angiography, 29.1% of modality revenue |
| Leading application | Stable chest pain and chronic coronary syndrome assessment, 38.4% of application revenue |
| Leading end use | Hospital-based cardiac centers, 62.7% of end-use revenue |
| Key players | GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems, Abbott, Heartflow |
Source: Analyst synthesis from authoritative sources, 2026.
Three factors keep market growth intact. Coronary disease burden remains large, with the American Heart Association estimating 254.28 million people living with ischemic heart disease globally in 2021. The 2024 ESC chronic coronary syndrome guidelines strengthened the role of CCTA in front-end rule-out and risk estimation, which supports scanner, software, and post-processing demand. Hospitals are also moving toward more selective invasive angiography, which increases the value of physiology-guided and intravascular imaging in cases that reach the cath lab.
Across tracked geographies, India sets the pace at 6.8% CAGR. China follows at 6.4%. South Korea follows at 5.9%. The United States follows at 5.3%. Germany follows at 4.8%. The United Kingdom follows at 4.6%. Japan follows at 4.4%.
The coronary heart disease diagnostic imaging market covers revenue tied to imaging tests, software, and image-guided diagnostic workflows used to detect, characterize, risk-stratify, or confirm coronary atherosclerotic disease and ischemia. The market includes non-invasive anatomical imaging, non-invasive functional imaging, and invasive diagnostic coronary imaging used before revascularization or as part of ischemia-guided decision support.
Market scope includes coronary computed tomography angiography, coronary calcium scoring used in coronary risk workup, stress echocardiography, SPECT myocardial perfusion imaging, PET myocardial perfusion imaging, CMR perfusion imaging, invasive coronary angiography, and adjunctive intravascular imaging or coronary physiology tools used in diagnostic decision making. Revenue coverage includes scanner use, imaging episodes, radiopharmaceutical-linked imaging revenue, and advanced post-processing or AI analysis linked to coronary disease diagnosis. Segmentation spans modality, application, end use, care setting, technology layer, and geography.
The scope excludes therapeutic coronary intervention revenue, stents and structural implants, cardiac rhythm imaging unrelated to coronary disease, general chest imaging not used for coronary workup, and population screening programs not connected to diagnostic evaluation of suspected or established coronary heart disease.
Primary Research: FMI analysts reviewed official clinical guidelines, public-health burden estimates, utilization statistics, and company disclosures from imaging vendors and cardiac workflow providers.
Desk Research: Data collection consolidated materials from the American Heart Association, ESC, OECD, NHS England, and official company disclosures covering coronary CT, PET MPI, ultrasound AI, and intravascular imaging to establish verifiable baseline parameters.
Market Sizing and Forecasting: Baseline values were derived from global ischemic heart disease burden, the share of patients entering imaging-led diagnostic pathways, modality mix by guideline position, and weighted revenue per imaging episode, and then cross-checked against disease prevalence, utilization intensity, reimbursement proxies, vendor launches, and adoption evidence from NHS and USA cardiac imaging pathways through 2036.
Data validation and update cycle: Projections were tested against prevalence trends, clinical pathway changes, utilization indicators, and disclosed vendor actions, with periodic review to keep the forecast aligned with changes in imaging practice and product positioning.
Coronary disease remains the largest cardiovascular disease category by mortality and one of the largest by prevalence. That keeps the diagnostic funnel large across ambulatory cardiology, emergency assessment, and hospital-based chronic coronary syndrome management.
Clinical pathways are moving earlier toward imaging. The 2024 ESC chronic coronary syndrome guideline recommends CCTA in individuals with low or moderate likelihood of obstructive disease and recommends stress echo, SPECT or PET MPI, or CMR perfusion imaging in moderate or high-likelihood cases.
Hospitals are investing in workflow-linked cardiac imaging instead of stand-alone image acquisition. AI-based plaque analysis, integrated CCTA review, CT-guided cath lab planning, and higher-value PET MPI workflows are lifting revenue per case even when invasive angiography volumes are managed more selectively.
Demand is expanding because coronary imaging now supports more than diagnosis alone. Anatomical definition, ischemia quantification, scar assessment, plaque characterization, and procedural planning are increasingly connected within one pathway. That raises the value of modalities that can either rule out disease early or sharpen revascularization decisions later in the care sequence.
The shift toward CCTA-first pathways is a direct growth driver. ESC guidance gave CCTA a Class I recommendation in low to moderate likelihood chronic coronary syndrome. NHS England has already scaled AI-supported coronary CT pathways across 56 hospitals, and Heartflow reported real-world data from 90,553 patients at 27 NHS hospital sites. Those pathway shifts support scanners, reconstruction software, post-processing, and follow-on functional assessment.
Nuclear and MR imaging remain important because CT does not answer every question. PET MPI, SPECT MPI, and CMR perfusion are used when functional significance, myocardial blood flow, or scar characterization matter. GE HealthCare stated that about six million MPI procedures are undertaken each year in the United States alone. That installed clinical habit creates a resilient base for nuclear imaging even as CT expands.
Invasive imaging is not disappearing. It is becoming more concentrated in patients with stronger disease likelihood, severe symptoms, or lesions of uncertain functional significance. That favors high-value cath-lab diagnostics including pressure assessment and intravascular imaging. The result is a market that grows from both front-end non-invasive imaging and later-stage image-guided diagnostic refinement.
The market is segmented by modality, application, end use, care setting, technology layer, and region. By modality, the market includes coronary computed tomography angiography, stress echocardiography, SPECT myocardial perfusion imaging, PET myocardial perfusion imaging, CMR perfusion imaging, and invasive coronary angiography with adjunctive physiology or intravascular imaging. By application, the market covers stable chest pain and chronic coronary syndrome assessment, acute chest pain and emergency triage, post-myocardial infarction or post-revascularization follow-up, ischemia burden quantification, and pre-operative coronary evaluation.
Coronary computed tomography angiography is projected to hold 29.1% of modality revenue in 2026. The segment benefits from first-line placement in current chronic coronary syndrome guidance, faster scanner cycles, better motion correction, plaque analysis software, and wider hospital interest in using CT data for procedural planning. Revenue growth also reflects higher-value software attached to the scan rather than scan volume alone.
Stable chest pain and chronic coronary syndrome assessment are expected to capture 38.4% of application revenue in 2026. Most patients with suspected coronary disease enter diagnostic workup through outpatient referral, cardiology clinic evaluation, or elective chest-pain pathways. This segment draws demand across CCTA, stress echo, SPECT or PET MPI, and CMR, which gives it the broadest modality base in the market.
Hospital-based cardiac centers are projected to account for 62.7% of end-use revenue in 2026. Coronary imaging frequently needs contrast support, multi-modality selection, emergency backup, integrated reporting, or escalation to invasive angiography. Those requirements keep the highest-value imaging episodes in tertiary hospitals and large cardiac centers rather than stand-alone imaging sites.
The market is expanding through clinical necessity and pathway redesign. CT, PET, and software-linked coronary analysis are gaining share faster. Echo and SPECT remain large because they are embedded in existing care delivery.
Growth reflects a measurable shift toward imaging-based rule-out and risk stratification. The ESC guideline recommends CCTA for low to moderate likelihood disease and recommends functional imaging for patients with higher likelihood or unclear functional significance. This broadens the addressable market because more patients receive structured imaging before invasive confirmation.
The market faces friction from capital intensity and uneven expertise. High-end cardiac CT, PET, and perfusion MRI require specialized hardware, experienced readers, protocol control, and contrast or radiopharmaceutical support. OECD data show wide variation in national imaging intensity, which means growth can be slowed by capacity rather than by clinical demand.
Workflow-linked software is becoming a major source of value in coronary imaging. NHS England is using AI-supported CT pathways for suspected coronary heart disease. Heartflow has reported national-scale evidence for CCTA plus FFRct, and large imaging vendors are linking CT, PET MPI, ultrasound AI, and cath-lab planning into connected workflows.
.webp "Top Country Growth Comparison Coronary Heart Disease Diagnostic Imaging Market Cagr (2026 2036)")
Asia is likely to deliver the fastest revenue growth over the forecast period because disease burden is large and imaging infrastructure is still being built out. India and China combine large symptomatic populations with rising CT, cath-lab, and tertiary cardiac-care capacity.
The United States remains the largest national revenue pool because imaging intensity is high, nuclear cardiology remains large, and coronary CT, PET, and plaque-analysis reimbursement are improving. OECD data show the United States among the highest users of CT, MRI, and PET exams per capita.
Western Europe grows more steadily. The region benefits from guideline alignment and strong tertiary care networks, but capital budgeting and public reimbursement keep growth below the fastest Asian markets.
South Korea ranks above most developed markets on growth because scanner intensity is high, cardiovascular imaging capability is strong, and hospitals have moved quickly to adopt advanced CT pathways.
| Country | CAGR |
|---|---|
| India | 6.8% |
| China | 6.4% |
| South Korea | 5.9% |
| United States | 5.3% |
| Germany | 4.8% |
| United Kingdom | 4.6% |
| Japan | 4.4% |
The United States is projected to grow at a CAGR of 5.3% through 2036. Growth is supported by high imaging intensity, a large nuclear cardiology base, rapid commercialization of PET MPI, and expanding use of advanced CCTA review and plaque analysis.
The United Kingdom is projected to grow at a CAGR of 4.6% through 2036. NHS England has accelerated coronary CT adoption, but public-system budget discipline caps near-term revenue growth per site.
Germany is expected to grow at a CAGR of 4.8% through 2036. The market benefits from strong hospital infrastructure and broad access to high-end imaging, though replacement-driven spending is more common than greenfield capacity growth.
Japan is projected to grow at a CAGR of 4.4% through 2036. The country has advanced imaging capability but slower volume expansion because the installed base is already mature and population growth is weak.
China is expected to grow at a CAGR of 6.4% through 2036. Coronary imaging demand is rising with hospital upgrading, broader cardiac-center buildout, and a large burden of ischemic disease and metabolic risk factors.
India is projected to grow at a CAGR of 6.8% through 2036. Growth is driven by high coronary disease burden, rapid private-hospital expansion, and increasing use of CT-led diagnosis in major urban cardiac centers.
The competitive landscape is led by diversified imaging companies with strong CT, ultrasound, MRI, nuclear, or image-guided therapy portfolios. Market power depends on cardiac imaging quality, installed base, workflow software, and ability to link diagnosis to intervention planning.
GE HealthCare, Siemens Healthineers, Philips, and Canon Medical Systems compete across scanner platforms and cardiac workflow software. Their position is reinforced by long replacement cycles, service relationships, and the ability to bundle cardiology applications into broader imaging contracts.
Abbott and Philips are stronger in invasive coronary imaging and physiology-guided workflows. Heartflow and similar software-led companies compete in post-processing, FFRct, and plaque analysis rather than core hardware.
Competition increasingly centers on pathway control. Vendors that connect calcium scoring, CCTA review, perfusion analysis, plaque characterization, and cath-lab guidance are capturing more decision-making value in coronary workup pathways.
Major Industry Players
GE HealthCare and Siemens Healthineers remain the strongest large-platform competitors because they can support cardiac CT, PET-supporting workflows, enterprise imaging, and service coverage across large hospital networks.
Philips and Canon Medical Systems maintain strong positions in CT, ultrasound, and interventional workflow-linked imaging. Philips is particularly active in linking CT, ultrasound, and cath-lab guidance inside coronary care pathways.
Abbott and Heartflow hold differentiated positions in downstream coronary decision support. Abbott benefits from physiology and intravascular imaging used once patients reach invasive workup. Heartflow benefits from software that extracts more value from the existing CT scan.
| Company | Coronary CT Strength | Functional or Invasive Imaging Strength | Workflow Software | Geographic Reach |
|---|---|---|---|---|
| GE HealthCare | High | High | High | Strong |
| Siemens Healthineers | High | High | High | Strong |
| Philips | High | High | High | Strong |
| Canon Medical Systems | High | Medium | Medium | Moderate |
| Abbott | Low | High | Medium | Strong |
| Heartflow | Medium | Medium | High | Moderate |
Source: Analyst synthesis from authoritative sources, 2026. Ratings reflect relative positioning based on disclosed capabilities and market presence.
Major Global Players:
Emerging Players/Startups
| Metric | Value |
|---|---|
| Quantitative Units | USD 6.16 billion to USD 10.65 billion, at a CAGR of 5.6% |
| Market Definition | Revenue linked to non-invasive and invasive imaging used to detect, characterize, or confirm coronary heart disease and myocardial ischemia. |
| Segmentation | Modality: coronary computed tomography angiography, stress echocardiography, SPECT myocardial perfusion imaging, PET myocardial perfusion imaging, CMR perfusion imaging, invasive coronary angiography with adjunctive physiology or intravascular imaging. Application: stable chest pain and chronic coronary syndrome assessment, acute chest pain and emergency triage, post-myocardial infarction or post-revascularization follow-up, ischemia burden quantification, pre-operative coronary evaluation. End use: hospital-based cardiac centers, multispecialty hospitals, ambulatory cardiology clinics, diagnostic imaging centers. Care setting: outpatient elective workup, emergency department triage, inpatient diagnostics, cath-lab based diagnostic workup. Technology layer: stand-alone imaging, AI-assisted analysis, FFRct and plaque analysis, image-guided coronary planning. |
| Regions Covered | North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa |
| Countries Covered | United States, Canada, Germany, United Kingdom, France, Italy, Spain, Japan, South Korea, China, India, Australia, Brazil, GCC countries, South Africa |
| Key Companies Profiled | GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems, Abbott, Heartflow, Cleerly, Elucid |
| Forecast Period | 2026 to 2036 |
| Approach | Analyst-built hybrid top-down and bottom-up model using disease burden, clinical pathway guidance, official utilization indicators, and official vendor disclosures. |
| Historical Period | 2020 to 2025 |
How large is the demand for Coronary Heart Disease Diagnostic Imaging in the global market in 2026?
Demand for coronary heart disease diagnostic imaging in the global market is estimated at USD 6.16 billion in 2026.
What will be the market size by 2036?
Market size is projected to reach USD 10.65 billion by 2036.
What is the expected demand growth between 2026 and 2036?
Demand is expected to grow at a CAGR of 5.6% between 2026 and 2036.
Which modality is poised to lead by 2026?
Coronary computed tomography angiography leads the market in 2026 with a 29.1% share of modality revenue.
How are hospital-based cardiac centers driving adoption?
Hospital-based cardiac centers account for 62.7% of end-use revenue because advanced coronary workups often require multi-modality selection, contrast support, emergency backup, and escalation to invasive diagnostics when needed.
What is driving demand in the United States?
The United States is projected to grow at a CAGR of 5.3% through 2036, supported by high imaging intensity, a large nuclear cardiology base, wider PET MPI use, and stronger use of advanced CCTA analysis.
What does the market definition mean?
The market includes revenue tied to imaging tests and workflow tools used to detect, characterize, risk-stratify, or confirm coronary heart disease and myocardial ischemia.
How does the analyst validate the forecast?
The forecast is validated through a hybrid model using disease burden, clinical guidelines, official imaging utilization indicators, and official company disclosures, with cross-checks on modality mix, country adoption, and workflow value.
Full Research Suite comprises of:
Market outlook & trends analysis
Interviews & case studies
Strategic recommendations
Vendor profiles & capabilities analysis
5-year forecasts
8 regions and 60+ country-level data splits
Market segment data splits
12 months of continuous data updates
DELIVERED AS:
PDF EXCEL ONLINE
Coronary Heart Disease Diagnostic Imaging Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
